Clinical Trial Update: A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating E7090 as a monotherapy and in combination with other anticancer agents in ER-positive, HER2-negative recurrent/metastatic breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• E7090

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Breast Neoplasms | Phase 1 | Status: ACTIVE_NOT_RECRUITING